User hoodoomoovoo discusses their interest in stemcell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.
Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.
Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.
A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
A man who claimed to have regrown his hair using stemcell treatment, sparking a debate about its effectiveness and cost. Some users suggested he might be using other treatments or substances, while others shared their own experiences with stemcell therapy for hair loss.
DHT affects hair follicles, contributing to hair loss, but the exact mechanism is unclear. Treatments like finasteride and minoxidil are used to manage hair loss, though they may have side effects and varying effectiveness.
Elevated bile acids can inhibit the enzyme AKR1C2, leading to increased DHT levels, which may accelerate hair loss in those predisposed to androgenetic alopecia. Treatments mentioned include topical minoxidil and finasteride.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
High prolactin levels can cause hair loss, and finasteride may increase prolactin. Cabergoline or Vitamin B6 might lower prolactin, but combining them with finasteride requires caution.
Topical Finasteride doesn't directly reduce 5ar enzyme on scalp and has the same mechanism as oral, needing to go through the liver. Users debate the accuracy of this information and discuss various studies and experiences.
The conversation discusses various factors affecting hair loss, not just DHT, and mentions treatments like Minoxidil, finasteride, and melatonin. Some users report personal experiences with these treatments and hormone tests, while others speculate on the role of hormones like prolactin and cortisol in hair loss.
N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stemcells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.
A user proposed genetically engineering scalp stemcells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
The conversation is about a hair loss product that claims to use stemcells and ingredients like Capixyl, Redensyl, and Baicapil, with the user asking if anyone has looked into it. No specific treatments were discussed.
Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stemcells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stemcell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stemcells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Stemcell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
A US federal judge ruled that using patients' stemcells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stemcell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stemcell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
Pelage is developing a topical hair follicle stemcell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.